Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $1.6 million.

  • Axsome Therapeutics' Amortizatization of Intangibles rose 6.23% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 26.6%. This contributed to the annual value of $6.4 million for FY2024, which is 26.67% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Amortizatization of Intangibles is $1.6 million, which was up 6.23% from $1.6 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Amortizatization of Intangibles high stood at $1.6 million for Q3 2022, and its period low was $275000.0 during Q1 2022.
  • In the last 4 years, Axsome Therapeutics' Amortizatization of Intangibles had a median value of $1.6 million in 2023 and averaged $1.5 million.
  • In the last 5 years, Axsome Therapeutics' Amortizatization of Intangibles soared by 48181.82% in 2023 and then tumbled by 106.99% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Amortizatization of Intangibles stood at $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then changed by 0.0% to $1.6 million in 2025.
  • Its Amortizatization of Intangibles was $1.6 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.6 million in Q1 2025.